These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30856290)
41. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
42. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485 [TBL] [Abstract][Full Text] [Related]
43. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis. Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235 [TBL] [Abstract][Full Text] [Related]
44. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064 [TBL] [Abstract][Full Text] [Related]
45. Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. Cheng K; Ding Y; Zhao Y; Ye S; Zhao X; Zhang Y; Ji T; Wu H; Wang B; Anderson GJ; Ren L; Nie G Nano Lett; 2018 May; 18(5):3250-3258. PubMed ID: 29683683 [TBL] [Abstract][Full Text] [Related]
47. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511 [TBL] [Abstract][Full Text] [Related]
48. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment. Li J; Zhao M; Sun M; Wu S; Zhang H; Dai Y; Wang D ACS Appl Mater Interfaces; 2020 Nov; 12(45):50734-50747. PubMed ID: 33124808 [TBL] [Abstract][Full Text] [Related]
49. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Zhang YX; Zhao YY; Shen J; Sun X; Liu Y; Liu H; Wang Y; Wang J Nano Lett; 2019 May; 19(5):2774-2783. PubMed ID: 30943039 [TBL] [Abstract][Full Text] [Related]
50. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
51. Radiotherapy-Controllable Chemotherapy from Reactive Oxygen Species-Responsive Polymeric Nanoparticles for Effective Local Dual Modality Treatment of Malignant Tumors. Liu TI; Yang YC; Chiang WH; Hung CK; Tsai YC; Chiang CS; Lo CL; Chiu HC Biomacromolecules; 2018 Sep; 19(9):3825-3839. PubMed ID: 30044907 [TBL] [Abstract][Full Text] [Related]
52. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy. Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671 [TBL] [Abstract][Full Text] [Related]
53. Co-delivery Nano System of MS-275 and V-9302 Induces Pyroptosis and Enhances Anti-Tumor Immunity Against Uveal Melanoma. Ren H; Wu Z; Tan J; Tao H; Zou W; Cao Z; Wen B; Cai Z; Du J; Deng Z Adv Sci (Weinh); 2024 Aug; 11(31):e2404375. PubMed ID: 38889339 [TBL] [Abstract][Full Text] [Related]
54. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. Liu Y; Chen XG; Yang PP; Qiao ZY; Wang H Biomacromolecules; 2019 Feb; 20(2):882-892. PubMed ID: 30621390 [TBL] [Abstract][Full Text] [Related]
55. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442 [TBL] [Abstract][Full Text] [Related]
57. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Wang C; Wang J; Zhang X; Yu S; Wen D; Hu Q; Ye Y; Bomba H; Hu X; Liu Z; Dotti G; Gu Z Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467299 [TBL] [Abstract][Full Text] [Related]